The global melanoma therapeutics market size is calculated at USD 6.70 billion in 2024, grew to USD 7.39 billion in 2025, and is predicted to hit around USD 17.93 billion by 2034, expanding at a CAGR of 10.35% between 2024 and 2034. The North America melanoma therapeutics market size accounted for USD 2.75 billion in 2024 and is anticipated to grow at the fastest CAGR of 10.46% during the forecast year.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Melanoma Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Melanoma Therapeutics Market Revenue and Volume, by Product, 2024-2034
8.1.1. Chemotherapy
8.1.1.1. Market Revenue and Volume Forecast (2021-2034)
8.1.2. Immunotherapy
8.1.2.1. Market Revenue and Volume Forecast (2021-2034)
8.1.3. Targeted Therapy
8.1.3.1. Market Revenue and Volume Forecast (2021-2034)
8.1.4. Radiation Therapy
8.1.4.1. Market Revenue and Volume Forecast (2021-2034)
9.1. Melanoma Therapeutics Market Revenue and Volume, by Drug Type, 2024-2034
9.1.1. Branded Drugs
9.1.1.1. Market Revenue and Volume Forecast (2021-2034)
9.1.2. Generic Drugs
9.1.2.1. Market Revenue and Volume Forecast (2021-2034)
10.1. North America
10.1.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.1.3. U.S.
10.1.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.3.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.1.4.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.2. Europe
10.2.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.2.3. UK
10.2.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.3.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.2.4. Germany
10.2.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.4.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.2.5. France
10.2.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.5.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.2.6.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.3. APAC
10.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.3.3. India
10.3.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.3.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.3.4. China
10.3.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.4.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.3.5. Japan
10.3.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.5.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.3.6.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.4. MEA
10.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.4.3. GCC
10.4.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.3.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.4.4. North Africa
10.4.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.4.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.4.5. South Africa
10.4.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.5.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.4.6.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.5. Latin America
10.5.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.5.3. Brazil
10.5.3.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.3.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Volume Forecast, by Product (2021-2034)
10.5.4.2. Market Revenue and Volume Forecast, by Drug Type (2021-2034)
11.1. Johnson & Johnson Private Limited (U.S.)
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Mylan N.V. (U.S.)
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Sun Pharmaceutical Industries Limited (India)
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Sanofi S.A. (France)
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Bayer AG (Germany)
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Lilly (U.S.)
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Merck & Co., Inc. (U.S.)
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. GSK plc (U.K.)
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
11.9. Novartis AG (Switzerland)
11.9.1. Company Overview
11.9.2. Product Offerings
11.9.3. Financial Performance
11.9.4. Recent Initiatives
11.10. AbbVie Inc. (U.S.)
11.10.1. Company Overview
11.10.2. Product Offerings
11.10.3. Financial Performance
11.10.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample